Healthcare Equipment and Supplies
Company Overview of CellAegis Devices Inc.
CellAegis Devices Inc. focuses on the design, development, manufacture, and distribution of medical devices. It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company is based in Toronto, Canada.
139 Mulock Avenue
Toronto, ON M6N 1G9
Key Executives for CellAegis Devices Inc.
Vice President of Corporate Development
Compensation as of Fiscal Year 2012.
CellAegis Devices Inc. Key Developments
CellAegis Devices Inc. Receives Marketing Authorization from Health Canada for the Autoric(Tm) Device
Mar 7 13
CellAegis Devices Inc. announced that it has received marketing authorization from Health Canada that allows for the commercial introduction in Canada of the company's autoRIC(TM) Device for Remote Ischemic Conditioning (RIC). Health Canada has granted a Medical Device Class III license for use of the autoRIC Device to provide non-invasive RIC for adult patients undergoing cardiothoracic surgery or interventional cardiothoracic procedures, as well as for patients with evolving myocardial infarction. Offering a safe and accurate method to automate RIC at the point of care, CellAegis' autoRIC Device is intended to reduce tissue injury from heart procedures or heart attacks in a hospital or ambulance setting or in the home as directed by a healthcare professional.
CellAegis Devices Inc. Receives an Investigational Testing Approval from Health Canada for autoRIC(TM) Device
Feb 27 13
CellAegis Devices Inc. announced that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC(TM) Device for Chronic Remote Ischemic Conditioning (CRIC). In a Canadian Institutes of Health Research (CIHR)-sponsored Phase II, randomized, double-blind, placebo-controlled, multi-center clinical study, CRIC will be evaluated for its ability to reduce adverse left ventricular remodeling following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). This is the third clinical trial to incorporate CellAegis' autoRIC Device. The Phase II study design for the clinical program calls for the enrollment of 82 adult patients treated emergently with primary PCI for STEMI involving the Left Anterior Descending (LAD) artery within 12 hours of onset of symptoms of a heart attack. Patients will be randomized 1:1 to either: a) a treatment group (CRIC) receiving CRIC using CellAegis' autoRIC Device programmed to give four cycles of controlled blood occlusion (ischemia) in a limb via inflation of the Device cuff to a pressure of 200 mm Hg for 5 minutes, followed by resumed blood flow (reperfusion), or b) a control group (SHAM) wearing an identical autoRIC Device, which is inflated only to 10 mm Hg such that no limb ischemia occurs. All patients will have initiated CRIC or SHAM using CellAegis' autoRIC Device prior to the PCI procedure and then will use the Device once-daily (4 cycles each day) for a 28-day period post-PCI.
CellAegis Devices Inc. Presents at OneMedForum SF 2013 - Emerging Company Finance Conference, Jan-09-2013 12:00 PM
Dec 12 12
CellAegis Devices Inc. Presents at OneMedForum SF 2013 - Emerging Company Finance Conference, Jan-09-2013 12:00 PM. Venue: Sir Francis Drake Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 21, 2013
February 19, 2013